Fund moves
602KShares reported
Among this manager's largest new positions for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Jun 17, 2026 · Filed Jun 22, 2026
The CEO of Nasus Pharma paid $20K out of pocket for Nasus Pharma shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$20,305
Shares × reported transaction price
<$25K
+4.2%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 2 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 2 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +6.1% | +1.8% | +4.3% |
| 30 days | −6.3% | +0.6% | −6.9% |
| 90 days | +4.2% | +5.4% | −1.2% |
Past results only. Not a forecast.
Fund moves
Among this manager's largest new positions for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Apr 22 · filed 1 day later
The CEO of Nasus Pharma paid $11K out of pocket for Nasus Pharma shares.
Insider buying
Traded Mar 31 · filed 1 day later
The CEO of Nasus Pharma paid $31K out of pocket for Nasus Pharma shares. Shares held went up 240% with this purchase.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Dan Benjamin Teleman, Chief Executive Officer's past purchases, 90 days after disclosure: 3 buys, median −1.2 pts vs S&P 500, beat it 1 of 3 times. Past results, not a forecast.